Lifeline offered for ebola patients in outbreak zones
NCT ID NCT03576690
Summary
This program provides emergency access to an experimental three-antibody treatment called REGN-EB3 for people sick with Ebola virus disease. It is for patients in outbreak regions who are not eligible for the main clinical trials, including children and pregnant women. The goal is to control the disease and improve survival during active outbreaks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.